Portal de Periódicos da CAPES

18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer

2016; Elsevier BV; Volume: 15; Issue: 3 Linguagem: Inglês

10.1016/j.clgc.2016.12.029

1938-0682

Frederik L. Giesel, Claudia Kesch, Mijin Yun, Jens Cardinale, Uwe Haberkorn, Klaus Kopka, Clemens Kratochwil, Boris Hadaschik,

Radiopharmaceutical Chemistry and Applications

Clinical Practice Points•To date, several radioactive tracers for imaging primary and recurrent prostate cancer are undergoing active investigation.•In this case report fluorine-18 (18F)–prostate-specific membrane antigen (PSMA)-1007 positron emission tomography (PET)/computed tomography imaging was performed, to our knowledge, for the first time in a patient with biochemical recurrence (prostate-specific antigen [PSA] 0.08 μg/L) after radical prostatectomy and adjuvant radiation.•Seventeen lymph nodes with increased tracer uptake along the retroperitoneum and iliac arteries were detected. Therefore, early treatment with intermittent androgen deprivation was initiated instead of locoregional salvage therapy.•Hence, 18F-PSMA-1007 PET imaging at very low PSA levels provided critical information to correctly restage disease. •To date, several radioactive tracers for imaging primary and recurrent prostate cancer are undergoing active investigation.•In this case report fluorine-18 (18F)–prostate-specific membrane antigen (PSMA)-1007 positron emission tomography (PET)/computed tomography imaging was performed, to our knowledge, for the first time in a patient with biochemical recurrence (prostate-specific antigen [PSA] 0.08 μg/L) after radical prostatectomy and adjuvant radiation.•Seventeen lymph nodes with increased tracer uptake along the retroperitoneum and iliac arteries were detected. Therefore, early treatment with intermittent androgen deprivation was initiated instead of locoregional salvage therapy.•Hence, 18F-PSMA-1007 PET imaging at very low PSA levels provided critical information to correctly restage disease.